Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT-774312: A novel CRTH2 antagonist.

Géhin M, Lott D, Farine H, Issac M, Strasser D, Sidharta P, Dingemanse J.

Basic Clin Pharmacol Toxicol. 2019 Jun;124(6):711-721. doi: 10.1111/bcpt.13197. Epub 2019 Feb 11.

PMID:
30589994
2.

Assessment of Peripheral Serotonin Synthesis Using Stable Isotope-Labeled Tryptophan.

Gehin M, Welford RWD, Garzotti M, Vercauteren M, Groenen PMA, Nayler O, Sidharta PN, Dingemanse J.

Clin Pharmacol Ther. 2018 Dec;104(6):1260-1267. doi: 10.1002/cpt.1087. Epub 2018 May 10.

PMID:
29663345
3.

A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.

Berger RMF, Gehin M, Beghetti M, Ivy D, Kusic-Pajic A, Cornelisse P, Grill S, Bonnet D; FUTURE-3 investigators.

Br J Clin Pharmacol. 2017 Aug;83(8):1734-1744. doi: 10.1111/bcp.13267. Epub 2017 Mar 23.

4.

Pediatric Development of Bosentan Facilitated by Modeling and Simulation.

Zisowsky J, Géhin M, Kusic-Pajic A, Krause A, Beghetti M, Dingemanse J.

Paediatr Drugs. 2017 Apr;19(2):121-130. doi: 10.1007/s40272-016-0206-0.

PMID:
28078552
5.

Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.

Steinhorn RH, Fineman J, Kusic-Pajic A, Cornelisse P, Gehin M, Nowbakht P, Pierce CM, Beghetti M; FUTURE-4 study investigators.

J Pediatr. 2016 Oct;177:90-96.e3. doi: 10.1016/j.jpeds.2016.06.078. Epub 2016 Aug 5.

PMID:
27502103
6.

Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis.

Géhin M, Sidharta PN, Dingemanse J.

Pharmacology. 2016;98(3-4):111-4. doi: 10.1159/000446583. Epub 2016 May 18.

PMID:
27189212
7.

CYP2C9 involvement in ACT-453859 metabolism.

Géhin M, Dingemanse J, Sidharta PN.

J Clin Pharmacol. 2015 Dec;55(12):1433. doi: 10.1002/jcph.593. No abstract available.

PMID:
26768086
8.

Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection.

Krause A, Zisowsky J, Strasser DS, Gehin M, Sidharta PN, Groenen PMA, Dingemanse J.

Clin Pharmacokinet. 2016 Jul;55(7):813-821. doi: 10.1007/s40262-015-0354-3.

PMID:
26692193
9.

Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection.

Gehin M, Desnica B, Dingemanse J.

Int J Antimicrob Agents. 2015 Nov;46(5):576-81. doi: 10.1016/j.ijantimicag.2015.07.015. Epub 2015 Sep 3.

PMID:
26419191
10.

A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects.

Géhin M, Strasser DS, Zisowsky J, Farine H, Groenen PM, Dingemanse J, Sidharta PN.

J Clin Pharmacol. 2015 Jul;55(7):787-97. doi: 10.1002/jcph.478. Epub 2015 Mar 30.

PMID:
25655470
11.

Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.

Gehin M, Sidharta PN, Gnerre C, Treiber A, Halabi A, Dingemanse J.

Eur J Clin Pharmacol. 2015 Jan;71(1):15-23. doi: 10.1007/s00228-014-1767-x. Epub 2014 Oct 18.

PMID:
25323804
12.

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.

Dingemanse J, Gehin M, Cruz HG, Hoever P.

Drug Des Devel Ther. 2014 Apr 28;8:397-403. doi: 10.2147/DDDT.S62118. eCollection 2014.

13.

Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.

Dingemanse J, Cruz HG, Gehin M, Hoever P.

J Pharm Sci. 2014 May;103(5):1548-56. doi: 10.1002/jps.23916. Epub 2014 Mar 6.

PMID:
24604243
14.

[Acute abdominal and lumbar pain in the adult].

Géhin M, Reibel N, de Korwin JD.

Rev Prat. 2009 Nov 20;59(9):1281-2. French. No abstract available.

PMID:
19961088
15.

[Acute abdominal and lumbar pain in the adult].

Géhin M, Reibel N, de Korwin JD.

Rev Prat. 2009 Sep 20;59(7):1013-23. French. No abstract available.

PMID:
19839479
16.

Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2.

Mödder UI, Monroe DG, Fraser DG, Spelsberg TC, Rosen CJ, Géhin M, Chambon P, O'Malley BW, Khosla S.

J Biol Chem. 2009 Jul 10;284(28):18767-77. doi: 10.1074/jbc.M109.000836. Epub 2009 May 7.

17.

Insidious adrenocortical insufficiency underlies neuroendocrine dysregulation in TIF-2 deficient mice.

Patchev AV, Fischer D, Wolf SS, Herkenham M, Götz F, Gehin M, Chambon P, Patchev VK, Almeida OF.

FASEB J. 2007 Jan;21(1):231-8. Epub 2006 Nov 29.

PMID:
17135362
18.

Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse.

Mukherjee A, Soyal SM, Fernandez-Valdivia R, Gehin M, Chambon P, Demayo FJ, Lydon JP, O'Malley BW.

Mol Cell Biol. 2006 Sep;26(17):6571-83.

19.

Partially redundant functions of SRC-1 and TIF2 in postnatal survival and male reproduction.

Mark M, Yoshida-Komiya H, Gehin M, Liao L, Tsai MJ, O'Malley BW, Chambon P, Xu J.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4453-8.

20.

SRC-1 and TIF2 control energy balance between white and brown adipose tissues.

Picard F, Géhin M, Annicotte J, Rocchi S, Champy MF, O'Malley BW, Chambon P, Auwerx J.

Cell. 2002 Dec 27;111(7):931-41.

21.

The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP.

Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P.

Mol Cell Biol. 2002 Aug;22(16):5923-37.

22.

Thyroid function in mice with compound heterozygous and homozygous disruptions of SRC-1 and TIF-2 coactivators: evidence for haploinsufficiency.

Weiss RE, Gehin M, Xu J, Sadow PM, O'Malley BW, Chambon P, Refetoff S.

Endocrinology. 2002 Apr;143(4):1554-7.

PMID:
11897715
23.

Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists.

Géhin M, Vivat V, Wurtz JM, Losson R, Chambon P, Moras D, Gronemeyer H.

Chem Biol. 1999 Aug;6(8):519-29.

24.

[Results of the treatment of breast cancer by combined tumorectomy and high dose radiotherapy].

PAPILLON J, DARGENT M, MONTBARON JF, DUTOU L, GEHIN M.

Ann Radiol (Paris). 1962;5:485-97. French. No abstract available.

PMID:
13941313
25.

[2 new cases of spotted dystrophy of the cornea].

RAVAULT M, GEHIN M, LAURENT C.

Bull Soc Ophtalmol Fr. 1961 May-Jun;5:485-7. French. No abstract available.

PMID:
14490619
26.

[A new case of nodular corneal dystrophy of the Salzmann type].

HUGONNIER R, RAVAULT M, GEHIN M.

Bull Soc Ophtalmol Fr. 1961 May-Jun;5:483-5. French. No abstract available.

PMID:
14036435

Supplemental Content

Support Center